- Home
- NVVE vs ZVSA Comparison
NVVE vs ZVSA Comparison
Compare NVVE & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVE
- ZVSA
- Stock Information
- Founded
- NVVE 1996
- ZVSA 2014
- Country
- NVVE United States
- ZVSA United States
- Employees
- NVVE N/A
- ZVSA N/A
- Industry
- NVVE Oil Refining/Marketing
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- NVVE Energy
- ZVSA Health Care
- Exchange
- NVVE Nasdaq
- ZVSA Nasdaq
- Market Cap
- NVVE 2.8M
- ZVSA 2.5M
- IPO Year
- NVVE N/A
- ZVSA N/A
- Fundamental
- Price
- NVVE $2.82
- ZVSA $1.10
- Analyst Decision
- NVVE
- ZVSA Strong Buy
- Analyst Count
- NVVE 0
- ZVSA 1
- Target Price
- NVVE N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- NVVE 11.5K
- ZVSA 243.8K
- Earning Date
- NVVE 11-12-2024
- ZVSA 11-14-2024
- Dividend Yield
- NVVE N/A
- ZVSA N/A
- EPS Growth
- NVVE N/A
- ZVSA N/A
- EPS
- NVVE N/A
- ZVSA N/A
- Revenue
- NVVE $5,144,831.00
- ZVSA N/A
- Revenue This Year
- NVVE $200.61
- ZVSA N/A
- Revenue Next Year
- NVVE $109.43
- ZVSA N/A
- P/E Ratio
- NVVE N/A
- ZVSA N/A
- Revenue Growth
- NVVE N/A
- ZVSA N/A
- 52 Week Low
- NVVE $2.82
- ZVSA $0.98
- 52 Week High
- NVVE $72.70
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- NVVE 30.04
- ZVSA 41.83
- Support Level
- NVVE $3.31
- ZVSA $0.99
- Resistance Level
- NVVE $3.69
- ZVSA $1.20
- Average True Range (ATR)
- NVVE 0.22
- ZVSA 0.08
- MACD
- NVVE -0.05
- ZVSA 0.04
- Stochastic Oscillator
- NVVE 0.00
- ZVSA 54.55
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.